NEWS - Dec 9, 2024 Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017 Read more
NEWS - Dec 4, 2024 Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance Read more
NEWS - Nov 19, 2024 Relmada Therapeutics to Present at Jefferies London Healthcare Conference Read more
NEWS - Nov 14, 2024 Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease Read more
NEWS - Nov 7, 2024 Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Read more
NEWS - Nov 4, 2024 Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 Read more
NEWS - Aug 7, 2024 Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Read more
NEWS - Aug 5, 2024 Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024 Read more
NEWS - Jun 18, 2024 Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry Read more
NEWS - Jun 10, 2024 Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Read more
